CLVT
Clarivate Plc
CLVT trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over CLVT overall, supported by stronger fundamentals and stronger valuation.
CLVT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Healthy | |
| Weak |
CLVT's cash flow is currently healthy, but its revenue, profitability and balance sheet are under pressure.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CLVT PE Valuation
CLVT has no meaningful PE right now: it lost money over the past year.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
CLVT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Decline | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CLVT's earnings and revenue to decline, though with profitability improving.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CLVT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.62 | — |
| Q3 2026 | -$0.61 | -$0.04 |
| Q2 2026 | -$0.52 | +$0.10 |
| Q1 2026 | -$0.21 | +$0.76 |
| Q4 2025 | -$0.30 | +$0.66 |
| Q3 2025 | -$0.57 | +$1.41 |
| Q2 2025 | -$0.62 | +$1.28 |
| Q1 2025 | -$0.97 | +$0.68 |
| Q4 2024 | -$0.96 | +$0.51 |
CLVT is still losing money, but far less than before: $0.61 per share over the past year, against $6.35 at its worst in mid-2023.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CLVT on earnings quality, reporting a profit while its opponent remains loss making.
CLVT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $481.6M | -23% |
| Q2 2026 | $587.3M | -5.5% |
| Q1 2026 | $585.5M | -1.4% |
| Q4 2025 | $617M | -6.9% |
| Q3 2025 | $623.1M | +0.1% |
| Q2 2025 | $621.4M | -4.4% |
| Q1 2025 | $593.7M | -4.4% |
| Q4 2024 | $663M | -3% |
CLVT's revenue has slid since its 2022 peak: $482M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.3% | +1.3 points |
| Q2 2026 | -34% | -35 points |
| Q1 2026 | 5.2% | +8.7 points |
| Q4 2025 | 6.7% | +16 points |
| Q3 2025 | 7.1% | +3.6 points |
| Q2 2025 | 1.1% | +38 points |
| Q1 2025 | -3.5% | -4.3 points |
| Q4 2024 | -9.4% | +106 points |
CLVT's operating margin was 8.3% last quarter, up 1.3 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CLVT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CLVT on profitability, with a higher operating margin.
CLVT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $110.2M | -4.6% |
| Q2 2026 | $44M | -13% |
| Q1 2026 | $78.9M | -28% |
| Q4 2025 | $89.2M | +51% |
| Q3 2025 | $115.5M | -8.6% |
| Q2 2025 | $50.3M | -17% |
| Q1 2025 | $110.3M | -1.3% |
| Q4 2024 | $59.1M | -53% |
CLVT still generates free cash flow, though less than at its 2023 peak: $322M over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CLVT on cash flow, with more consistent year-over-year improvement.
CLVT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +300K shares |
| 1 year | -4.3% | -28.6M shares |
| 3 years | -4.7% | -31.2M shares |
| 5 years | +4.7% | +28.6M shares |
| Available history | +86% | +297M shares |
CLVT has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $18.1M |
| Q4 2025 | $75M |
| Q3 2025 | $50M |
| Q2 2025 | $49.5M |
| Q1 2025 | $50M |
| Q4 2024 | $100M |
CLVT spent $93M buying back its own shares over the past year, down 63% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CLVT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.1x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 4.6x | High |
| Q4 2025 | 4.9x | High |
| Q3 2025 | 5.7x | High |
| Q2 2025 | 6.1x | High |
| Q1 2025 | 9.7x | High |
| Q4 2024 | 9.4x | High |
CLVT's net debt is about 6.1 years of its operating earnings (EBITDA), up from 5.7 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over CLVT on leverage, with a lower net debt burden relative to earnings.
CLVT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 66.9 | Neutral |
CLVT's weekly RSI is 54 (neutral) and its Stochastic is 67 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CLVT PE vs Technology Sector
| Metric | CLVT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CLVT has no meaningful PE right now: it lost money over the past year.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CLVT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.85 | 24% above |
| 20 week MA | $1.99 | 16% above |
| 50 week MA | $2.38 | 3.4% below |
| 100 week MA | $3.29 | 30% below |
| 200 week MA | $5.46 | 58% below |
CLVT has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CLVT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.0 | $30.1 | +77% |
| 2021 | $30.1 | $24.7 | -18% |
| 2022 | $24.7 | $8.16 | -67% |
| 2023 | $8.16 | $9.26 | +13% |
| 2024 | $9.26 | $5.12 | -45% |
| 2025 | $5.12 | $3.50 | -32% |
| 2026 YTD | $3.50 | $2.30 | -34% |
CLVT has finished lower in four of the last six years. It's down 34% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over CLVT on returns for 2026, with the stronger performance.